Precipio Inc (PRPO) Stock Price, Quote & News

Company Profile

Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Hav...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 203 787 7888

Website: www.precipiodx.com

Address:

4 Science Park, 3rd Floor, New Haven, United States

diddy48 Sep. 12 at 6:47 PM

$PRPO this is what AI says about the chart set up

0 · Reply

topstockalerts Sep. 11 at 2:04 AM

$PRPO this one is putting together a pretty convincing case.

0 · Reply

Loren77 Sep. 10 at 9:10 PM

$PRPO You know what will happen next 🚀

1 · Reply

Bruces4 Sep. 8 at 12:17 PM

$PRPO Utter nonsense. CEO has indicated they will not need funding near term and are cash flow positive and only improving from here. Call him if you have any questions...but nice try.

0 · Reply

MollyJones567 Sep. 6 at 9:01 PM

$PRPO risk/reward looks ugly here. Dilution risk is real and the chart shows no strength to back up the hype. Chasing this feels like picking up pennies in front of a steamroller. Not seeing a reason to be brave on the long side right now.

2 · Reply

Bruces4 Sep. 4 at 8:02 PM

$PRPO Beautiful bounce off the 200 forming a suh....WEEEET hammer candle reverseal on the daily...

0 · Reply

Bruces4 Sep. 4 at 4:51 PM

$PRPO Back to tag the 200...

0 · Reply

Bruces4 Sep. 4 at 4:49 PM

$PRPO Adding a bit each day cheaper and cheaper...

0 · Reply

SinnagodKosher Sep. 4 at 4:12 PM

$PRPO Same bullshid, different day 🤷🏻‍♂️

0 · Reply

Messi0321 Sep. 3 at 11:57 PM

$PRPO now is the last chance to add some if u wanno add.

0 · Reply

Precipio Earnings Call Transcript: Q2 2026

Aug 17, 2026, 5:00 PM EDT - 26 days ago

Precipio Quarterly report: Q2 2026

Aug 17, 2026, 5:00 PM EDT - 26 days ago

Precipio Earnings release: Q2 2026

Aug 14, 2026, 4:00 PM EDT - 4 weeks ago

Precipio Announces Q2-2026 Financial Results

Jul 31, 2026, 4:00 PM EDT - 6 weeks ago

Precipio Announces Q2-2026 Shareholder Update Call

Jun 17, 2026, 12:00 PM EDT - 2 months ago

Precipio Transcript: Planet MicroCap Las Vegas 2026

Jun 17, 2026, 12:00 PM EDT - 2 months ago

Precipio Slides: FY 2026

Jun 15, 2026, 10:00 AM EDT - 2 months ago

Precipio Transcript: AGM 2026

Jun 12, 2026, 1:00 PM EDT - 3 months ago

Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting

Jun 11, 2026, 5:00 PM EDT - 3 months ago

Precipio to Present at the Planet MicroCap Las Vegas

May 18, 2026, 5:00 PM EDT - 3 months ago

Precipio Earnings Call Transcript: Q1 2026

May 18, 2026, 5:00 PM EDT - 3 months ago

Precipio Quarterly report: Q1 2026

May 18, 2026, 5:00 PM EDT - 3 months ago

Precipio Earnings release: Q1 2026

2026-05-14T22:07:57.000Z - 4 months ago

Precipio reports Q1 revenue $6.71M vs $6.69M last year

May 14, 2026, 5:00 PM EDT - 4 months ago

Precipio Announces Q1 2026 Financial Results

May 13, 2026, 5:00 PM EDT - 4 months ago

Management team's 2025 market-based Options have vested

May 6, 2026, 5:00 PM EDT - 4 months ago

Precipio Announces Q1-2026 Shareholder Update Call

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Precipio Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Precipio Proxy statement: Proxy filing

Apr 2, 2026, 5:00 PM EDT - 5 months ago

Precipio Earnings Call Transcript: Q4 2025

Apr 2, 2026, 5:00 PM EDT - 5 months ago

Precipio Annual report: Q4 2025

Mar 12, 2026, 5:00 PM EDT - 6 months ago

Precipio Announces Q4 and year-end 2025 Shareholder Update Call

2026-03-10T13:05:12.000Z - 6 months ago

Precipio announces publication in Journal of Clinical Pathology

2026-02-25T14:36:32.000Z - 6 months ago

Precipio reports FY25 revenue $24M vs. $18.5M last year

Feb 25, 2026, 9:30 AM EST - 6 months ago

Precipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-Year

2026-01-15T14:11:34.000Z - 8 months ago

Precipio announces steps towards clean balance sheet

Jan 15, 2026, 9:00 AM EST - 8 months ago

Precipio Takes Major Steps Toward a Clean Balance Sheet

Dec 5, 2025, 10:00 AM EST - 9 months ago

Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting

2025-12-04T13:05:47.000Z - 9 months ago

Precipio identifies unauthorized access to isolated storage

Dec 4, 2025, 8:00 AM EST - 9 months ago

Precipio Identifies Unauthorized Access to Isolated Storage; No Operational Impact

Nov 14, 2025, 4:30 PM EST - 10 months ago

Precipio Announces its Q3-2025 Financial Results

Nov 14, 2025, 2:00 AM EST - 10 months ago

Precipio Earnings Call Transcript: Q3 2025

Nov 14, 2025, 2:00 AM EST - 10 months ago

Precipio Quarterly report: Q3 2025

Nov 14, 2025, 2:00 AM EST - 10 months ago

Precipio Earnings release: Q3 2025

Nov 4, 2025, 5:00 PM EST - 10 months ago

Precipio Announces Q3-2025 Shareholder Update Call

2025-09-02T14:05:22.000Z - 1 year ago

Precipio terminates at-the-market instrument with Alliance Global

Aug 13, 2025, 5:00 PM EDT - 1 year ago

Precipio Announces its Q2-2025 Financial Results

Aug 13, 2025, 3:00 AM EDT - 1 year ago

Precipio Earnings Call Transcript: Q2 2025

Aug 13, 2025, 3:00 AM EDT - 1 year ago

Precipio Quarterly report: Q2 2025

Aug 13, 2025, 3:00 AM EDT - 1 year ago

Precipio Earnings release: Q2 2025

Jul 31, 2025, 4:30 PM EDT - 1 year ago

Precipio Announces Q2-2025 Shareholder Update Call

Jul 11, 2025, 4:30 PM EDT - 1 year ago

Precipio Enters Into Agreement With Warrant Holder To Exercise Majority Of Warrants As Cashless

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Precipio Proxy statement: Proxy Filing

May 14, 2025, 5:00 PM EDT - 1 year ago

Precipio Announces its Q1-2025 Financial Results

May 14, 2025, 3:00 AM EDT - 1 year ago

Precipio Earnings Call Transcript: Q1 2025

May 14, 2025, 3:00 AM EDT - 1 year ago

Precipio Quarterly report: Q1 2025

May 14, 2025, 3:00 AM EDT - 1 year ago

Precipio Earnings release: Q1 2025

May 1, 2025, 5:00 PM EDT - 1 year ago

Precipio Announces Q1-2025 Shareholder Update Call

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Precipio Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Precipio Proxy statement: Proxy Filing

2025-04-23T19:15:17.000Z - 1 year ago

Precipio trading resumes

2025-04-23T19:05:16.000Z - 1 year ago

Precipio trading halted, volatility trading pause

Mar 27, 2025, 3:00 AM EDT - 1 year ago

Precipio Earnings Call Transcript: Q4 2024

Mar 27, 2025, 3:00 AM EDT - 1 year ago

Precipio Annual report: Q4 2024

Mar 17, 2025, 5:00 PM EDT - 1 year ago

Precipio Announces Q4 and year-end 2024 Shareholder Update Call

2025-02-25T14:45:45.000Z - 1 year ago

Precipio achieves positive adjusted EBITDA, cash flow in Q4

Feb 25, 2025, 9:30 AM EST - 1 year ago

Precipio Achieves Key Q4-2024 Financial Goals: Positive Adjusted EBITDA and Positive Cash Flow (unaudited)

Jan 16, 2025, 5:00 PM EST - 1 year ago

Precipio grants senior management performance-based awards instead of traditional time-vested ESOPs

Nov 6, 2024, 5:00 PM EST - 1 year ago

Precipio Announces Q3-2024 Shareholder Update Call

Nov 6, 2024, 2:00 AM EST - 1 year ago

Precipio Earnings Call Transcript: Q3 2024

Nov 6, 2024, 2:00 AM EST - 1 year ago

Precipio Quarterly report: Q3 2024

2024-10-08T14:05:18.000Z - 1 year ago

Precipio expands Bloodhound MPN panel by adding CALR mutation subtyping

Oct 8, 2024, 10:00 AM EDT - 1 year ago

Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping

Sep 6, 2024, 4:00 PM EDT - 2 years ago

Precipio Announces Employee Stock Option Plan Repricing

Aug 15, 2024, 5:00 PM EDT - 2 years ago

Precipio Announces Q2-2024 Shareholder Update Call

Aug 13, 2024, 3:00 AM EDT - 2 years ago

Precipio Earnings Call Transcript: Q2 2024

Aug 13, 2024, 3:00 AM EDT - 2 years ago

Precipio Quarterly report: Q2 2024

2024-07-25T13:02:10.000Z - 2 years ago

Precipio reports unaudited CBFO for Q2 was $0.3M

Jul 25, 2024, 9:00 AM EDT - 2 years ago

Precipio Reports $0.3M cash generated by operations (unaudited) in Q2-2024, as the company advances towards breakeven

2024-07-17T13:06:50.000Z - 2 years ago

Precipio sees Q2 revenue $4.4M vs. $3.4M in Q1

Jul 17, 2024, 9:00 AM EDT - 2 years ago

Precipio Reports $4.4M for Q2-2024 (unaudited) Revenues, a leap of 30% from Q1-2024

Jun 13, 2024, 4:00 PM EDT - 2 years ago

Precipio Inc. Announces Adjournment of Annual Meeting of Stockholders

Jun 13, 2024, 8:00 AM EDT - 2 years ago

Precipio Proxy statement: Proxy Filing

Jun 13, 2024, 8:00 AM EDT - 2 years ago

Precipio Proxy statement: Proxy Filing

2024-06-12T13:03:29.000Z - 2 years ago

Precipio says pathology revenue ‘heading back towards’ breakeven point

May 14, 2024, 3:00 AM EDT - 2 years ago

Precipio Quarterly report: Q1 2024

May 6, 2024, 5:00 PM EDT - 2 years ago

Precipio Secures a short-term $500K Credit Facility

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Precipio Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Precipio Proxy statement: Proxy Filing

Apr 1, 2024, 5:00 PM EDT - 2 years ago

Precipio Transcript: Status Update

2024-04-01T20:45:00.000Z - 2 years ago

Precipio to hold a conference call

2024-04-01T16:45:25.000Z - 2 years ago

Precipio to hold a conference call

Mar 29, 2024, 3:00 AM EDT - 2 years ago

Precipio Annual report: Q4 2023

Mar 25, 2024, 5:00 PM EDT - 2 years ago

Precipio Announces Year end 2023 Shareholder Update Call

Feb 13, 2024, 10:00 AM EST - 2 years ago

Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY

2024-02-06T15:05:28.000Z - 2 years ago

Precipio trading resumes

2024-02-06T15:01:42.000Z - 2 years ago

Precipio, Cardinal Health enter distribution agreement for HemeScreen portfolio

CAH

2024-02-06T15:00:28.000Z - 2 years ago

Precipio trading halted, volatility trading pause

Feb 6, 2024, 10:00 AM EST - 2 years ago

Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer

2024-01-23T15:04:05.000Z - 2 years ago

Precipio reports Q4 cash burn from operations below $100,000

Jan 23, 2024, 10:00 AM EST - 2 years ago

Precipio's Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter

Jan 17, 2024, 10:30 AM EST - 2 years ago

Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan

Jan 2, 2024, 9:00 AM EST - 2 years ago

Precipio Announces Christina Valauri joins the Board of Directors

Dec 14, 2023, 4:30 PM EST - 2 years ago

Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024

Nov 16, 2023, 5:00 PM EST - 2 years ago

Precipio Announces Q3-2023 Shareholder Update Call

Nov 13, 2023, 2:00 AM EST - 2 years ago

Precipio Earnings Call Transcript: Q3 2023

Nov 13, 2023, 2:00 AM EST - 2 years ago

Precipio Quarterly report: Q3 2023

Oct 18, 2023, 9:00 AM EDT - 2 years ago

Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022

Oct 3, 2023, 10:00 AM EDT - 2 years ago

Precipio's Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023

Sep 28, 2023, 9:00 AM EDT - 2 years ago

Precipio Continues to Sign New HemeScreen™ Customers

Sep 25, 2023, 11:00 AM EDT - 2 years ago

Precipio Reduces Product Revenue Result Needed for Cash Flow Breakeven

Sep 21, 2023, 9:00 AM EDT - 2 years ago

Precipio Takes Final Step Towards Regaining Nasdaq Compliance

Sep 13, 2023, 9:30 AM EDT - 3 years ago

Precipio's Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan

Aug 11, 2023, 3:00 AM EDT - 3 years ago

Precipio Earnings Call Transcript: Q2 2023

Aug 11, 2023, 3:00 AM EDT - 3 years ago

Precipio Quarterly report: Q2 2023

Aug 10, 2023, 5:00 PM EDT - 3 years ago

Precipio Announces Q2-2023 Shareholder Update Call

Aug 8, 2023, 9:00 AM EDT - 3 years ago

Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel

Aug 3, 2023, 9:00 AM EDT - 3 years ago

Precipio's Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards Breakeven

Aug 1, 2023, 9:00 AM EDT - 3 years ago

Precipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023

Jul 7, 2023, 8:00 AM EDT - 3 years ago

Precipio Registration statement: Registration Filing

Jun 14, 2023, 9:49 AM EDT - 3 years ago

Precipio's Omnia™ Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy

Jun 13, 2023, 9:00 AM EDT - 3 years ago

Precipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® Technology

diddy48 Sep. 12 at 6:47 PM

$PRPO this is what AI says about the chart set up

0 · Reply

topstockalerts Sep. 11 at 2:04 AM

$PRPO this one is putting together a pretty convincing case.

0 · Reply

Loren77 Sep. 10 at 9:10 PM

$PRPO You know what will happen next 🚀

1 · Reply

Bruces4 Sep. 8 at 12:17 PM

$PRPO Utter nonsense. CEO has indicated they will not need funding near term and are cash flow positive and only improving from here. Call him if you have any questions...but nice try.

0 · Reply

MollyJones567 Sep. 6 at 9:01 PM

2 · Reply

Bruces4 Sep. 4 at 8:02 PM

$PRPO Beautiful bounce off the 200 forming a suh....WEEEET hammer candle reverseal on the daily...

0 · Reply

Bruces4 Sep. 4 at 4:51 PM

$PRPO Back to tag the 200...

0 · Reply

Bruces4 Sep. 4 at 4:49 PM

$PRPO Adding a bit each day cheaper and cheaper...

0 · Reply

SinnagodKosher Sep. 4 at 4:12 PM

$PRPO Same bullshid, different day 🤷🏻‍♂️

0 · Reply

Messi0321 Sep. 3 at 11:57 PM

$PRPO now is the last chance to add some if u wanno add.

0 · Reply

Bruces4 Sep. 3 at 4:14 PM

$PRPO 90% of today's volume is off market. Hope this marks the low of the "handle"...

1 · Reply

Loren77 Sep. 3 at 2:02 PM

$PRPO The cup-and-handle pattern has completed perfectly. An uptrend is imminent.

0 · Reply

Loren77 Sep. 3 at 1:41 PM

$PRPO the volume!!! 😲

0 · Reply

Damadama Sep. 2 at 2:48 PM

$PRPO volume in forte aumento

0 · Reply

SinnagodKosher Sep. 1 at 5:03 PM

$PRPO ya, ya…wake me up at $65

0 · Reply

Messi0321 Aug. 31 at 7:18 PM

$PRPO touched 32$ once, could not break it, now this week or next will touch 32 again, will see if this can breaks $32 2nd time.

1 · Reply

Hellroaring Aug. 28 at 12:53 PM

$PRPO ~ Sold off awhile back, waiting for a couple other tickers to pop so I can get back in here before she blows up. Bought one share this morning so I don't have to switch screens ... she's a bit constipated this morning 😀 Checked bolume after my big buy asaaaand -- volume is a whole 1 share 😀😀😀😀😀

1 · Reply

Drac Aug. 27 at 5:07 PM

$PRPO shorties be careful you are threading on shallow waters all news are good with this stock

0 · Reply

Loren77 Aug. 26 at 2:00 PM

$PRPO I’ve set an alert for $100 or higher. I’m ready to sell everything if I see a massive "God candle". Then I’ll wait patiently to buy back in.

1 · Reply

Loren77 Aug. 26 at 1:56 PM

$PRPO It has been a year and four months since the low of $3.90. I increasingly get the feeling that a massive spike—accompanied by millions in volume—is approaching, designed to let the "smart money" (which has been accumulating since then) sell off their entire position. 😖

0 · Reply

Bader0555 Aug. 25 at 8:49 PM

$PRPO Those who currently own shares should be patient, and you will see insane increases, perhaps exceeding 200%. Remember that the number of free-floating shares is only 1.560 million, and the short selling rate is also very high.

0 · Reply

Bader0555 Aug. 25 at 8:43 PM

$PRPO If the price surpasses $33, we will see very significant increases, perhaps reaching $75 or even much higher. I wouldn't rule out the price reaching nearly $100, as the stock has very strong catalysts.

1 · Reply

Market Cap	48.91M
Revenue (ttm)	24.05M
Net Income (ttm)	-360,000.00
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1.50%
Debt to Equity Ratio	0.02

Volume	89,100
Avg Vol	135,844
Day's Range	N/A - N/A
Shares Out	1.79M
Stochastic %K	52%
Beta	1.32
Analysts	Strong Buy
Price Target	$40.00